Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “JS001”

61 trials

Showing 20 of 61 results

Testing effectiveness (Phase 2)UnknownNCT03848611
What this trial is testing

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Who this might be right for
Non-small Cell Lung Cancer
AnewPharma 20
Testing effectiveness (Phase 2)Looking for participantsNCT05173246
What this trial is testing

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Who this might be right for
Esophageal Small Cell Carcinoma
Sun Yat-sen University 43
Large-scale testing (Phase 3)UnknownNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Large-scale testing (Phase 3)Study completedNCT03829969
What this trial is testing

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Who this might be right for
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Shanghai Junshi Bioscience Co., Ltd. 514
Testing effectiveness (Phase 2)UnknownNCT04316351
What this trial is testing

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Guangzhou Institute of Respiratory Disease 60
Testing effectiveness (Phase 2)UnknownNCT03941795
What this trial is testing

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma

Who this might be right for
Advanced Mucosal Melanoma
Peking University Cancer Hospital & Institute 99
Large-scale testing (Phase 3)Active Not RecruitingNCT06505837
What this trial is testing

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Who this might be right for
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 395
Early research (Phase 1)Study completedNCT03167853
What this trial is testing

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Early research (Phase 1)WithdrawnNCT05262842
What this trial is testing

JS001+IMP4297 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT05033392
What this trial is testing

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Stomach Neoplasms
Wan He 62
Testing effectiveness (Phase 2)UnknownNCT04605796
What this trial is testing

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)
Shanghai Junshi Bioscience Co., Ltd. 54
Testing effectiveness (Phase 2)UnknownNCT04856631
What this trial is testing

Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Who this might be right for
Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd. 88
Testing effectiveness (Phase 2)UnknownNCT04523883
What this trial is testing

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 316
Testing effectiveness (Phase 2)Looking for participantsNCT06791070
What this trial is testing

RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum

Who this might be right for
Paget Disease, ExtramammaryScrotum Disease
Fujian Medical University Union Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT03867370
What this trial is testing

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04085276
What this trial is testing

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Who this might be right for
Triple-Negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd. 531
Testing effectiveness (Phase 2)UnknownNCT04527068
What this trial is testing

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Who this might be right for
Refractory Metastatic Colorectal CancerpMMRMSS
Second Affiliated Hospital, School of Medicine, Zhejiang University 50
Early research (Phase 1)UnknownNCT04206358
What this trial is testing

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Who this might be right for
Melanoma
Peking University Cancer Hospital & Institute 30
Testing effectiveness (Phase 2)UnknownNCT04503902
What this trial is testing

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 46
Large-scale testing (Phase 3)Temporarily pausedNCT03777579
What this trial is testing

First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Who this might be right for
Triple Negative Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 375
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation